New lessons for an old problem: ASSET open-label extension.

[1]  A. Kaneko,et al.  Longterm Efficacy and Safety of Abatacept in Patients with Rheumatoid Arthritis Treated in Routine Clinical Practice: Effect of Concomitant Methotrexate after 24 Weeks , 2015, The Journal of Rheumatology.

[2]  G. Raghu,et al.  Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis , 2020, Arthritis & rheumatology.

[3]  M. Mayes,et al.  Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. , 2020, The Lancet. Rheumatology.

[4]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[5]  M. Matucci-Cerinic,et al.  Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. , 2020, Seminars in arthritis and rheumatism.

[6]  Tammara A. Wood,et al.  Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial , 2020, Arthritis & rheumatology.

[7]  A. Schäffer,et al.  Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations , 2014, Nature Medicine.

[8]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[9]  G. Helmlinger,et al.  Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis , 2020, Oncoimmunology.

[10]  M. Dougados,et al.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.